Johnson & Johnson (JNJ) snagged Shockwave Medical (SWAV) in a $13.1 billion deal that the Dow Jones giant says will accelerate its shift into higher-growth markets.
X
Shockwave uses intravascular lithotripsy, or IVL, to crack calcifications in the arteries. This allows the blood to flow easier, reducing pain and the risk of heart attacks. Traditionally, patients undergo atherectomy, which uses a small drill to dig through the calcifications. But this can lead to embolic debris flowing downstream and clogging the arteries again.
IVL “doesn’t disrupt the calcium to a degree it’s liberated,” Shockwave Chief Executive Doug Godshall said in a 2022 interview. “The vessel expands dramatically.”
Shockwave stock has surged 68% year to date, as of Thursday’s close, with takeover speculation as one of the driving forces. Last year, rumors suggested Boston Scientific (BSX) could buy it. In morning trades on today’s stock market, Shockwave Medical shares rose 1.7% to 325.47, while J&J stock fell a fraction to 152.34.
Shockwave Medical: An Expert In Cardiovascular Tech
The deal values Shockwave stock at $355 per share and is expected to close in mid-2024.
Johnson & Johnson says the transaction will be slightly dilutive to its adjusted earnings this year and next.
Adding Shockwave Medical will further expand J&J medtech’s expertise in cardiovascular intervention. Needham analyst Mike Matson notes J&J previously bought Abiomed and Laminar. Abiomed makes implantable circulatory support devices. Laminar makes a device that treats a heart condition, lowering the risk of stroke.
“We believe that the J&J offer fairly values Shockwave, do not expect any antitrust issues due to a lack of product overlap and think that a higher bid is unlikely,” he said in a report.
He downgraded Shockwave stock to a hold rating from buy.
Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Staar Surgical, A Lasik Rival, Just Crushed Quarterly Views; But Is Its 2026 Target Too Aggressive?
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
Best Growth Stocks To Buy And Watch
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today
Futures: Jobs Due After Ugly Reversal; Dow Giant To Buy Shockwave Medical
Barbara Terrio is a seasoned business journalist, delving into the world of finance, startups, and entrepreneurship. With a knack for demystifying complex economic trends, she helps readers navigate the business landscape. Outside of her reporting, Barbara is an advocate for financial literacy and enjoys mentoring aspiring entrepreneurs.
